单位:[1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China[2]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China[3]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China[4]Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China[5]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China浙江大学医学院附属第一医院[6]Shandong First Med Univ, Shandong Canc Hosp & Inst, Tai An, Shandong, Peoples R China[7]Shandong Acad Med Sci, Tai An, Shandong, Peoples R China[8]Sichuan Univ, West China Sch Med, Chengdu, Peoples R China四川大学华西医院[9]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[10]Jilin Canc Hosp, Changchun, Peoples R China[11]Cent South Univ, Hunan Canc Hosp, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha, Peoples R China[12]Xinjiang Med Univ, Affiliated Canc Hosp, Urumqi, Peoples R China[13]Linyi Canc Hosp, Linyi, Shandong, Peoples R China[14]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[15]Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China[16]Fourth Mil Med Univ, Tangdu Hosp, Xian, Peoples R China[17]Harbin Med Univ, Affiliated Tumor Hosp, Harbin, Peoples R China[18]Liaoning Canc Hosp, Shenyang, Liaoning, Peoples R China[19]Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China[20]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[21]HUTCHMED, Shanghai, Peoples R China
第一作者单位:[1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Lu S.,Fang J.,Li X.,et al.Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC[J].ANNALS OF ONCOLOGY.2022,33:S27-S27.doi:10.1016/j.annonc.2022.02.011.
APA:
Lu, S.,Fang, J.,Li, X.,Cao, L.,Zhou, J....&Weiguo, S..(2022).Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC.ANNALS OF ONCOLOGY,33,
MLA:
Lu, S.,et al."Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC".ANNALS OF ONCOLOGY 33.(2022):S27-S27